Trial record 5 of 27 for:    Neuroleptic Malignant Syndrome

Study of the Causes of the Breakdown of Muscle Fibers in Hospitalized Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2009 by National Taiwan University Hospital.
Recruitment status was  Recruiting
Information provided by:
National Taiwan University Hospital Identifier:
First received: November 25, 2009
Last updated: November 30, 2009
Last verified: November 2009
  1. Analyze the various causes of breakdown of muscle fibers in hospitalized patients.
  2. Analyze the characteristics of these patients in Taiwan (including the drugs history, risk factors and the incidence of complications).

Acute Renal Failure
Neuroleptic Malignant Syndrome

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Rhabdomyolysis - A Retrospective Study in Hospitalized Patients

Resource links provided by NLM:

Further study details as provided by National Taiwan University Hospital:

Estimated Enrollment: 2500
Study Start Date: November 2009
Estimated Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Detailed Description:
  1. Find the causes of breakdown of muscle fibers in hospitalized patients through medical record review.

    • especially drug-related
  2. Find the risk factors of muscle fibers breakdown.

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who admitted to The National Taiwan University Hospital during 2003/1/1~2008/12/31 with rhabdomyolysis or related muscle diseases dignosis and clinical presentation.

Inclusion Criteria:

  • Patients who admitted to The National Taiwan University Hospital during 2003/1/1~2008/12/31 with the following discharge diagnosis: myoglobinuria, rhabdomyolysis, myopathy, toxic myopathy, malignant hyperthermia, neuroleptic malignant syndrome, polymyositis, myalgia and had acute neuromuscular illness presentations and serum creatinine kinase (CK) more than 5 times the upper limit of normal (male > 900 IU/L; female > 835 IU/L).

Exclusion Criteria:

  • Patients with recent myocardial infarction or stroke, unless clinical history, examination, or electromyography showed a concomitant myopathy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01022450

Contact: Fe-Lin L Wu, MSCP, PhD +886-2-23123456 ext 88389
Contact: Kwan-Dun Wu, MD, PhD +886-2-23123456 ext 65014

National Taiwan University Hospital Recruiting
Taipei, Taiwan, 10051
Contact: Kwan-Dun Wu, MD, PhD    886-2-23123456 ext 65014   
Principal Investigator: Fe-Lin L Wu, MSCP, PhD         
Sub-Investigator: Kwan-Dun Wu, MD, PhD         
Sponsors and Collaborators
National Taiwan University Hospital
Principal Investigator: Fe-Lin L Wu, MSCP, PhD Graduate Institute of Clinical Pharmacy, National Taiwan University
  More Information

No publications provided

Responsible Party: Fe-Lin Lin Wu / Associate Professor, Director, Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University Identifier: NCT01022450     History of Changes
Other Study ID Numbers: 200911033R
Study First Received: November 25, 2009
Last Updated: November 30, 2009
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
acute renal failure
neuroleptic malignant syndrome
Pharmaceutical Preparations
Hydroxymethylglutaryl-CoA Reductase Inhibitors
creatine kinase

Additional relevant MeSH terms:
Neuroleptic Malignant Syndrome
Neurotoxicity Syndromes
Acute Kidney Injury
Renal Insufficiency
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Chemically-Induced Disorders
Kidney Diseases
Muscular Diseases
Musculoskeletal Diseases
Nervous System Diseases
Urologic Diseases
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Enzyme Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on November 27, 2015